uses of tacrolimus in behcet disease

Conditions: Oral Ulcer; Behcet Syndrome

Summary: background: oral ulceration is the earliest and commonest manifestation of behcet's disease (bd). minor aphthous like ulcers (\<10 mm in diameter) are the most common type (85%); major or herpetiform ulcers are less frequent. it is occurred about in egypt; 3.6/100,000 % and high recurrence rate with traditional treatment. colchicine is the first line of treatment in mucocutaneous manifestation of bd through its anti-inflammatory effect. tacrolimus oral gel is safe and effective in treating aphthous ulcers in many diseases. objectives: to compare the clinical efficacy of topical tacrolimus versus oral colchicine upon disease activity, pain and ulcer severity in oral ulcer associated with bd. study design: a randomized double -blinded trial. setting: rheumatology clinic, assiut university hospital and faculty of dental medicine, alazhar university, assiut branch outpatient's clinic. methods: 40 bd participants (\> 3 months taken traditional treatment with persistent active oral ulceration). they have been equally randomized into either group i (colchicine and topically applied tacrolimus), or group ii (colchicine only). measurements: behcet's disease current activity form (bdcaf), ulcer severity score (uss) and visual analog scale (vas) pre-injection, then re-evaluated postinjection at four-time points (15 days, 1st, 2nd and 3rd months) and determination of natural killer (nk) cells number in salival wash before treatment (at base line) and after the treatment (after 3 months)

background: oral ulceration is the earliest and commonest manifestation of behcet's disease (bd). minor aphthous like ulcers (\<10 mm in diameter) are the most common type (85%); major or herpetiform ulcers are less frequent. it is occurred about in egypt; 3.6/100,000 % and high recurrence rate with traditional treatment. colchicine is the first line of treatment in mucocutaneous manifestation of bd through its anti-inflammatory effect. tacrolimus oral gel is safe and effective in treating aphthous ulcers in many diseases. objectives: to compare the clinical efficacy of topical tacrolimus versus oral colchicine upon disease activity, pain and ulcer severity in oral ulcer associated with bd. study design: a randomized double -blinded trial. setting: rheumatology clinic, assiut university hospital and faculty of dental medicine, alazhar university, assiut branch outpatient's clinic. methods: 40 bd participants (\> 3 months taken traditional treatment with persistent active oral ulceration). they have been equally randomized into either group i (colchicine and topically applied tacrolimus), or group ii (colchicine only). measurements: behcet's disease current activity form (bdcaf), ulcer severity score (uss) and visual analog scale (vas) pre-injection, then re-evaluated postinjection at four-time points (15 days, 1st, 2nd and 3rd months) and determination of natural killer (nk) cells number in salival wash before treatment (at base line) and after the treatment (after 3 months)

Eligibility criteria:
inclusion criteria: * active oral ulcers for behcet's disease exclusion criteria: * patients who received biological therapy comorbid systemic diseases allergy to tarcolimus drug.